{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:05:57Z","timestamp":1790701557407,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ahjo.2026.100865","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T15:34:10Z","timestamp":1788017650000},"page":"100865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cardiovascular disease risk in patients with and without metabolic dysfunction-associated steatotic liver disease: A clinical and subclinical evaluation"],"prefix":"10.1016","volume":"70","author":[{"given":"Mohamed Yousef Abdallah Y.","family":"Omar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amany Mansour E.","family":"El-mallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Gamal M.A.","family":"Bakr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Mahmoud E.","family":"Ragab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahjo.2026.100865_bb0005","series-title":"Noninvasive Diagnosis and Monitoring of Nonalcoholic Steatohepatitis: Present and Future","author":"Wieckowska","year":"2007"},{"issue":"4","key":"10.1016\/j.ahjo.2026.100865_bb0010","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/hep4.1155","article-title":"Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and meta-analysis","volume":"2","author":"Zhou","year":"2018","journal-title":"Hepatol. Commun."},{"issue":"3","key":"10.1016\/j.ahjo.2026.100865_bb0015","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.ahjo.2026.100865_bb0020","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ahjo.2026.100865_bb0025","series-title":"Increased Risk of Cardiovascular Disease in Non-alcoholic Fatty Liver Disease: Causal Effect or Epiphenomenon?","author":"Targher","year":"2008"},{"issue":"1","key":"10.1016\/j.ahjo.2026.100865_bb0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cld.1017","article-title":"Nonalcoholic fatty liver disease and cardiovascular disease","volume":"17","author":"Przybyszewski","year":"2021","journal-title":"Clin. Liver Dis. (Hoboken)"},{"issue":"2","key":"10.1016\/j.ahjo.2026.100865_bb0035","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jhep.2017.10.031","article-title":"Preclinical models of non-alcoholic fatty liver disease","volume":"68","author":"Santhekadur","year":"2018","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.ahjo.2026.100865_bb0040","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5152\/tjg.2022.22075","article-title":"Determining subclinical cardiovascular and cardiac diseases in patients with non-alcoholic fatty liver disease","volume":"34","author":"Karao\u011flan","year":"2023","journal-title":"Turk. J. Gastroenterol."},{"key":"10.1016\/j.ahjo.2026.100865_bb0045","series-title":"Epicardial Fat: A Novel Marker of Subclinical Atherosclerosis in Clinical Practice?","author":"Katsiki","year":"2017"},{"issue":"1","key":"10.1016\/j.ahjo.2026.100865_bb0050","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/STROKEAHA.120.030433","article-title":"Severity of nonalcoholic fatty liver disease and risk of future ischemic stroke events","volume":"52","author":"Xu","year":"2021","journal-title":"Stroke"},{"issue":"22","key":"10.1016\/j.ahjo.2026.100865_bb0055","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021654","article-title":"Nonalcoholic fatty liver disease and risk of heart failure among medicare beneficiaries","volume":"10","author":"Fudim","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ahjo.2026.100865_bb0060","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076388","article-title":"Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study","volume":"384","author":"Kim","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.ahjo.2026.100865_bb0065","author":"Targher"},{"key":"10.1016\/j.ahjo.2026.100865_bb0070","series-title":"Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-analysis","author":"Dulai","year":"2017"},{"issue":"6","key":"10.1016\/j.ahjo.2026.100865_bb0075","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstr\u00f6m","year":"2017","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.ahjo.2026.100865_bb0080","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.26156","article-title":"Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States","volume":"57","author":"Kim","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ahjo.2026.100865_bb0085","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1080\/07853890.2021.1974081","article-title":"High NAFLD fibrosis score in non-alcoholic fatty liver disease as a predictor of carotid plaque development: a retrospective cohort study based on regular health check-up data in China","volume":"53","author":"Yu","year":"2021","journal-title":"Ann. Med."},{"issue":"1","key":"10.1016\/j.ahjo.2026.100865_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.numecd.2024.10.006","article-title":"Elevated concurrent carotid atherosclerosis rates in patients with metabolic dysfunction-associated fatty liver disease (MAFLD) compared to non-alcoholic fatty liver disease (NAFLD): a cross-sectional observational study","volume":"35","author":"Chung","year":"2025","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.ahjo.2026.100865_bb0095","series-title":"Evaluation of Intima-media Thickness and Arterial Stiffness as Early Ultrasound Biomarkers of Carotid Artery Atherosclerosis","author":"Fern\u00e1ndez-Alvarez","year":"2022"},{"issue":"6","key":"10.1016\/j.ahjo.2026.100865_bb0100","doi-asserted-by":"crossref","first-page":"E168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ahjo.2026.100865_bb0105","series-title":"Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-art Review","author":"Stahl","year":"2019"},{"key":"10.1016\/j.ahjo.2026.100865_bb0110","series-title":"The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk","author":"Caussy","year":"2021"},{"issue":"1","key":"10.1016\/j.ahjo.2026.100865_bb0115","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-020-01207-9","article-title":"Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease","volume":"19","author":"Wu","year":"2020","journal-title":"Lipids Health Dis."},{"issue":"4","key":"10.1016\/j.ahjo.2026.100865_bb0120","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2016.12.020","article-title":"PNPLA3, TM6SF2, and MBOAT7 genotypes and coronary artery disease","volume":"152","author":"Simons","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ahjo.2026.100865_bb0125","series-title":"Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to be Answered","author":"Torres","year":"2019"},{"issue":"5","key":"10.1016\/j.ahjo.2026.100865_bb0130","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ahjo.2026.100865_bb0135","series-title":"EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-alcoholic Fatty Liver Disease","author":"Marchesini","year":"2016"},{"issue":"2","key":"10.1016\/j.ahjo.2026.100865_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2021-001850","article-title":"Association between non-alcoholic fatty liver disease and subclinical atherosclerosis in Western and Asian cohorts: an updated meta-analysis","volume":"8","author":"Wong","year":"2021","journal-title":"Open Heart"},{"issue":"1","key":"10.1016\/j.ahjo.2026.100865_bb0145","article-title":"Fibrosis score 4 index has an independent relationship with coronary artery diseases in patients with metabolic-associated fatty liver disease","volume":"15","author":"Namakchian","year":"2023","journal-title":"DiabetolMetabSyndr"},{"issue":"5","key":"10.1016\/j.ahjo.2026.100865_bb0150","first-page":"613","article-title":"The new pooled cohort equations risk calculator","volume":"31","author":"Preiss","year":"2015","journal-title":"Can. J. Cardiol."},{"issue":"9","key":"10.1016\/j.ahjo.2026.100865_bb0155","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.123.016465","article-title":"Impact of nonalcoholic hepatic steatosis on the warranty period of a coronary artery calcium score of 0: results from the multi-ethnic study of atherosclerosis","volume":"17","author":"Ichikawa","year":"2024","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"10.1016\/j.ahjo.2026.100865_bb0160","series-title":"Risk Scores for Prediction of Major Cardiovascular Events in Non-alcoholic Fatty Liver Disease: A No Man\u2019s Land?","author":"Gheorghe","year":"2023"},{"key":"10.1016\/j.ahjo.2026.100865_bb0165","series-title":"Biomarkers of Hepatic Dysfunction and Cardiovascular Risk","author":"Lee","year":"2023"},{"key":"10.1016\/j.ahjo.2026.100865_bb0170","author":"Eckel"},{"issue":"8","key":"10.1016\/j.ahjo.2026.100865_bb0175","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1210\/jc.2016-1525","article-title":"Nonalcoholic fatty liver disease is associated with coronary artery calcification development: a longitudinal study","volume":"101","author":"Park","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.ahjo.2026.100865_bb3600","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4070\/kcj.2025.0212","article-title":"Cardiovascular Implications in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review","volume":"56","author":"Batta","year":"2026","journal-title":"Korean Circ. J."},{"issue":"2","key":"10.1016\/j.ahjo.2026.100865_bb3700","article-title":"Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: Pathophysiology, diagnosis, and emerging therapeutic strategies","volume":"17","year":"2026","journal-title":"World J. Diabetes"},{"issue":"1","key":"10.1016\/j.ahjo.2026.100865_bb3800","doi-asserted-by":"crossref","DOI":"10.4330\/wjc.v18.i1.111954","article-title":"Metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction: A state-of-the-art review","volume":"18","author":"Brar","year":"2026","journal-title":"World J. Cardiol"},{"key":"10.1016\/j.ahjo.2026.100865_bb3900","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.117181","article-title":"Do biomarkers matter? Cardiovascular risk stratification in Asian metabolic dysfunction-associated steatotic liver disease in the era of fibrosis-centric assessment","author":"Goyal","year":"2026","journal-title":"World J. Gastroenterol."}],"container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602226001540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602226001540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:34:46Z","timestamp":1790699686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666602226001540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":39,"alternative-id":["S2666602226001540"],"URL":"https:\/\/doi.org\/10.1016\/j.ahjo.2026.100865","relation":{},"ISSN":["2666-6022"],"issn-type":[{"value":"2666-6022","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular disease risk in patients with and without metabolic dysfunction-associated steatotic liver disease: A clinical and subclinical evaluation","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal Plus: Cardiology Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahjo.2026.100865","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100865"}}